Published in AAPS J on August 01, 2009
Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther (2012) 1.87
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol (2013) 1.83
A Nonlinear Mixed Effects Approach for Modeling the Cell-To-Cell Variability of Mig1 Dynamics in Yeast. PLoS One (2015) 1.51
Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother (2012) 1.50
Population pharmacokinetic meta-analysis to bridge ferumoxytol plasma pharmacokinetics across populations. Clin Pharmacokinet (2015) 1.45
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol (2014) 1.38
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol (2013) 1.21
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics Syst Pharmacol (2016) 1.12
A fast method for testing covariates in population PK/PD Models. AAPS J (2011) 1.05
Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Chemother (2012) 1.04
Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar J (2012) 1.00
Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res (2010) 0.98
Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol (2010) 0.97
A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J (2012) 0.97
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol (2015) 0.96
Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother (2011) 0.96
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J (2012) 0.96
Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics. AAPS J (2010) 0.95
Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br J Clin Pharmacol (2012) 0.95
Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother (2011) 0.95
Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Br J Clin Pharmacol (2015) 0.94
Performance in population models for count data, part II: a new SAEM algorithm. J Pharmacokinet Pharmacodyn (2009) 0.94
Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol (2014) 0.93
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. Br J Clin Pharmacol (2017) 0.93
Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. Br J Clin Pharmacol (2011) 0.92
Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother (2015) 0.92
Model evaluation of continuous data pharmacometric models: Metrics and graphics. CPT Pharmacometrics Syst Pharmacol (2016) 0.89
Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. CPT Pharmacometrics Syst Pharmacol (2013) 0.89
Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci (2013) 0.87
Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother (2014) 0.87
OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics (2013) 0.87
A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. J Clin Pharmacol (2011) 0.86
Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol (2012) 0.85
Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J (2012) 0.85
Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother (2014) 0.85
Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients. Antimicrob Agents Chemother (2012) 0.85
Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol (2010) 0.85
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol (2014) 0.84
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol (2015) 0.84
Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect. Eur J Clin Pharmacol (2015) 0.84
Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children. Antimicrob Agents Chemother (2015) 0.84
A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients. AAPS J (2014) 0.83
Covariate selection in pharmacometric analyses: a review of methods. Br J Clin Pharmacol (2015) 0.83
Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria. Antimicrob Agents Chemother (2015) 0.82
Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. J Clin Pharmacol (2013) 0.82
Multiple imputation of missing covariates in NONMEM and evaluation of the method's sensitivity to η-shrinkage. AAPS J (2013) 0.82
Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib. CPT Pharmacometrics Syst Pharmacol (2015) 0.82
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol (2015) 0.81
Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. Antimicrob Agents Chemother (2013) 0.81
Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis. AAPS J (2011) 0.81
Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. Br J Clin Pharmacol (2014) 0.81
Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet (2014) 0.80
Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. Br J Clin Pharmacol (2010) 0.80
Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border. Antimicrob Agents Chemother (2015) 0.80
Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother (2015) 0.80
Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study. Br J Clin Pharmacol (2015) 0.79
Standard Error of Empirical Bayes Estimate in NONMEM® VI. Korean J Physiol Pharmacol (2012) 0.79
Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults. Antimicrob Agents Chemother (2015) 0.79
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients. Orphanet J Rare Dis (2011) 0.79
Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. Eur J Clin Pharmacol (2016) 0.78
Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates. AAPS J (2015) 0.78
ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics (2014) 0.78
Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test. J Pharmacokinet Pharmacodyn (2011) 0.78
Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics. CPT Pharmacometrics Syst Pharmacol (2014) 0.78
Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J Clin Pharmacol (2012) 0.78
Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia. Br J Clin Pharmacol (2016) 0.77
Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics. Pharmacogenet Genomics (2015) 0.77
The Population Pharmacokinetics of D-β-hydroxybutyrate Following Administration of (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate. AAPS J (2016) 0.77
Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol (2014) 0.77
Population Pharmacokinetic Modeling of Tribendimidine Metabolites in Opisthorchis viverrini-Infected Adults. Antimicrob Agents Chemother (2016) 0.77
Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. PLoS One (2016) 0.77
Evaluation of an extended grid method for estimation using nonparametric distributions. AAPS J (2009) 0.77
Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers. Clin Pharmacokinet (2016) 0.77
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. Antimicrob Agents Chemother (2016) 0.77
Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents. Clin Pharmacokinet (2017) 0.77
Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol (2016) 0.77
Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. Antimicrob Agents Chemother (2014) 0.76
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. PLoS One (2015) 0.76
Use of a linearization approximation facilitating stochastic model building. J Pharmacokinet Pharmacodyn (2014) 0.76
Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach. Eur J Clin Pharmacol (2012) 0.76
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer. Cancer Chemother Pharmacol (2015) 0.76
Inter occasion variability in individual optimal design. J Pharmacokinet Pharmacodyn (2015) 0.76
Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease. J Clin Pharmacol (2016) 0.76
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol (2014) 0.76
Population pharmacokinetic analysis of axitinib in healthy volunteers. Br J Clin Pharmacol (2014) 0.76
A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. Clin Pharmacokinet (2017) 0.76
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. Antivir Ther (2014) 0.76
Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis. J Vet Pharmacol Ther (2014) 0.76
An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol (2013) 0.76
Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. J Antimicrob Chemother (2014) 0.76
Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol (2016) 0.76
Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Med (2017) 0.76
Evaluation of effect of impaired renal function on lamivudine pharmacokinetics. Br J Clin Pharmacol (2014) 0.75
Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy. J Antimicrob Chemother (2014) 0.75
Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin. AAPS J (2015) 0.75
A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy. Br J Clin Pharmacol (2016) 0.75
Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. J Clin Pharmacol (2015) 0.75
Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (2013) 0.75
Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes. Diabetes Technol Ther (2014) 0.75
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed (1999) 8.87
Diagnosing model diagnostics. Clin Pharmacol Ther (2007) 4.17
Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm (1992) 3.97
The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm (1993) 3.66
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn (2007) 3.00
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res (2007) 2.51
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol (2002) 2.43
Forecasting individual pharmacokinetics. Clin Pharmacol Ther (1979) 2.41
Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci (1982) 2.34
Automated covariate model building within NONMEM. Pharm Res (1998) 2.32
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn (2003) 2.06
Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res (1995) 2.00
Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm (1998) 1.93
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother (2008) 1.79
Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn (2007) 1.63
Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J (2005) 1.59
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol (2006) 1.45
Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther (2008) 1.32
Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1997) 1.30
Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. Br J Clin Pharmacol (2001) 1.27
A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J (2005) 1.24
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol (2003) 1.18
Population pharmacokinetics of tobramycin. Br J Clin Pharmacol (1989) 1.07
Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. J Pharmacokinet Biopharm (1992) 1.03
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol (2006) 1.01
Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. Br J Clin Pharmacol (2004) 0.96
Evaluation of the nonparametric estimation method in NONMEM VI. Eur J Pharm Sci (2008) 0.95
Application of population pharmacokinetics to cladribine. BMC Pharmacol (2005) 0.95
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. Br J Clin Pharmacol (2008) 0.93
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther (2005) 0.92
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Clin Pharmacol Ther (1998) 0.89
Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol (2003) 0.89
Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Haematologica (2003) 0.86
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn (2007) 3.00
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res (2007) 2.51
Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn (2008) 2.50
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol (2002) 2.43
Handling data below the limit of quantification in mixed effect models. AAPS J (2009) 2.11
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci (2002) 1.72
Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn (2008) 1.59
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res (2011) 1.57
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol (2012) 1.48
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol (2002) 1.38
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother (2006) 1.36
Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res (2002) 1.30
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol (2005) 1.28
PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool. Comput Methods Programs Biomed (2012) 1.27
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED. J Pharmacokinet Pharmacodyn (2004) 1.24
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol (2004) 1.22
Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn (2002) 1.19
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol (2003) 1.18
Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn (2002) 1.17
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J (2012) 1.16
Semiparametric distributions with estimated shape parameters. Pharm Res (2009) 1.15
Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother (2012) 1.13
Performance in population models for count data, part I: maximum likelihood approximations. J Pharmacokinet Pharmacodyn (2009) 1.13
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther (2002) 1.08
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res (2006) 1.06
A fast method for testing covariates in population PK/PD Models. AAPS J (2011) 1.05
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol (2003) 1.04
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother (2013) 1.03
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn (2008) 1.01
Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn (2009) 1.01
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol (2006) 1.01
Mechanistic models for myelosuppression. Invest New Drugs (2003) 1.00
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models. AAPS J (2012) 0.99
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics (2008) 0.99
An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol (2007) 0.97
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother (2012) 0.97
Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. Br J Clin Pharmacol (2004) 0.96
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J (2012) 0.96
An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol (2007) 0.96
Evaluation of the nonparametric estimation method in NONMEM VI. Eur J Pharm Sci (2008) 0.95
Application of population pharmacokinetics to cladribine. BMC Pharmacol (2005) 0.95
Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. J Pharmacokinet Pharmacodyn (2010) 0.95
Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother (2011) 0.95
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol (2004) 0.94
A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res (2002) 0.94
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model. J Pharmacokinet Pharmacodyn (2005) 0.94
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. Br J Clin Pharmacol (2008) 0.93
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol (2002) 0.93
An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. J Clin Pharmacol (2009) 0.92
Simultaneous optimal experimental design on dose and sample times. J Pharmacokinet Pharmacodyn (2009) 0.92
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther (2005) 0.92
Modeling of red blood cell life-spans in hematologically normal populations. J Pharmacokinet Pharmacodyn (2012) 0.92
Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br J Clin Pharmacol (2003) 0.90
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res (2007) 0.89
Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol (2003) 0.89
An integrated model for the glucose-insulin system. Basic Clin Pharmacol Toxicol (2009) 0.89
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Invest New Drugs (2009) 0.88
Comparison of proportional and differential odds models for mixed-effects analysis of categorical data. J Pharmacokinet Pharmacodyn (2008) 0.88
A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J Pharmacokinet Pharmacodyn (2013) 0.88
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol (2005) 0.87
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. J Clin Pharmacol (2010) 0.87
A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A. Br J Clin Pharmacol (2013) 0.87
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol (2009) 0.86
Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Haematologica (2003) 0.86
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. Antivir Ther (2012) 0.86
An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers. Br J Clin Pharmacol (2007) 0.86
Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment. J Clin Pharmacol (2011) 0.86
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region. Neuroimage (2013) 0.85
Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model. J Pharmacokinet Pharmacodyn (2012) 0.85
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br J Clin Pharmacol (2004) 0.85
Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7. J Pharmacokinet Pharmacodyn (2014) 0.85
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin. J Clin Pharmacol (2011) 0.85
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. Br J Clin Pharmacol (2006) 0.85
Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model. J Pharmacol Exp Ther (2011) 0.85
Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis. AAPS J (2016) 0.84
Optimal adaptive design in clinical drug development: a simulation example. J Clin Pharmacol (2007) 0.84
A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed (2008) 0.84
The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion. J Pharmacokinet Pharmacodyn (2009) 0.84
Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling. Pharm Res (2014) 0.84
Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole. J Pharmacokinet Pharmacodyn (2002) 0.84
A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol (2011) 0.84
Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol (2009) 0.84
Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo. Cancer Chemother Pharmacol (2004) 0.84
Performance of three estimation methods in repeated time-to-event modeling. AAPS J (2011) 0.84
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs (2010) 0.83
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Invest New Drugs (2009) 0.83
A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol (2009) 0.83
Serial correlation in optimal design for nonlinear mixed effects models. J Pharmacokinet Pharmacodyn (2012) 0.83
Modeling sleep data for a new drug in development using markov mixed-effects models. Pharm Res (2011) 0.83